EGFR and breast carcinoma: Focused research has revealed promising strategies for treating this subtype of breast cancer, including platinum agents, epidermal growth factor receptor (EGFR)-targeted agents and poly(ADP-Ribose) polymerase (PARP) inhibitors; however, there is as yet no specific target for effective tailored therapy in this subgroup.